Hims & Hers Faces Regulatory Backlash Over GLP-1 Weight-Loss Pill Strategy

Hims & Hers Health is facing significant legal and regulatory challenges following its strategic expansion into compounded GLP-1 weight-loss medications. The company initially launched these treatments to drive revenue growth as its core sexual-health business reached maturity. However, the move has triggered aggressive legal pushback from Novo Nordisk and intensified scrutiny from the U.S. Food and Drug Administration (FDA). This development has accelerated a broader regulatory crackdown on drug compounding companies that produce versions of patented medications. Analysts view this situation as a major risk to Hims & Hers' growth catalysts, while potentially strengthening the patent positions of major pharmaceutical firms like Eli Lilly and Novo Nordisk.